Why is Beryl Drugs falling/rising?

As of 17-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 23.00, which reflects a decrease of 0.86 or 3.6%. The stock has underperformed its sector by 3.64% today and has been on a consecutive downward trend for the last three days, resulting in a total drop of 5.35%. Over the past week, the stock has fallen by 4.80%, and its year-to-date performance shows a significant decline of 36.38%. Despite having a relatively attractive valuation with a return on capital employed (ROCE) of 11 and trading at a discount compared to peers, the stock's profits have decreased by 37% over the past year, contributing to its negative performance.
In the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 1.56% over the past week and 5.83% year-to-date. The stock's liquidity is adequate, but there has been a notable decline in investor participation, with delivery volume dropping by nearly 40% against the five-day average. This lack of interest, combined with weak long-term fundamentals—such as a low EBIT to interest ratio and poor growth in net sales—suggests that investors are cautious about the company's future prospects, leading to its underperformance relative to the market.